Impact of long-term steroid therapy on epicardial and pericardial fat deposition: a cardiac MRI study by Daniel Kitterer et al.
Kitterer et al. Cardiovasc Diabetol  (2015) 14:130 
DOI 10.1186/s12933-015-0289-x
ORIGINAL INVESTIGATION
Impact of long-term steroid therapy 
on epicardial and pericardial fat deposition: a 
cardiac MRI study
Daniel Kitterer1, Joerg Latus1, Joerg Henes2, Stefan Birkmeier3, Maik Backes4, Niko Braun1, Udo Sechtem3, 
M. Dominik Alscher1, Heiko Mahrholdt3 and Simon Greulich3*
Abstract 
Background: Increased cardiac fat has been identified as a risk factor for coronary artery disease. Metabolic syn-
drome is associated with increased cardiac fat deposition. Steroids are known to imitate some effects of metabolic 
syndrome and are frequently used in patients with rheumatic disorders. Primary aim was to evaluate the impact of 
long-term steroid use on cardiac fat deposition in patients with rheumatic disorders. In addition, we sought to investi-
gate if this effect might be dose-dependent.
Methods: Patients were enrolled as follows: (1) rheumatic disorder; and (2) long-term steroid therapy, and (3) under-
went cardiovascular magnetic resonance (CMR) imaging. Patients were stratified in a high-dose (>7.5 mg prednisone 
equivalent/day for at least 6 months) and a low-dose steroid group (<7.5 mg prednisone equivalent/day) and com-
pared to steroid-naïve controls without rheumatic disorders.
Results: 122 patients were included (n = 61 steroid patients, n = 61 controls). N = 36 were classified as high-dose, 
n = 25 as low-dose steroid group. Steroid patients showed larger epicardial 5.7 [3.5–9.1] cm2 and pericardial 13.0 
[6.1–26.8] cm2 areas of fat than controls 4.2 [1.3–5.8] cm2/6.4 [1.6–15.4] cm2, p < 0.001, p < 0.01, respectively. High-
dose steroid patients had more epi- and pericardial fat both than controls: 7.2 [4.2–11.1] cm2 vs. 4.4 [1.0-6.0] cm2, 
p < 0.001; 18.6 [8.9–38.2] cm2 vs. 10.7 [4.7–26.8] cm2, p < 0.05, and patients in the low-dose steroid group (p < 0.01, 
p < 0.001, respectively).
Conclusion: The present data suggest increased cardiac fat deposition in steroid-treated patients with rheumatic 
disorders. Furthermore, this accumulation of cardiac fat seems to be dose-dependent, pointing towards a cumulative 
effect of steroids.
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Background
Coronary artery disease (CAD) is the leading cause of 
death in the western world [1]. Current clinical practice 
guidelines recommend strict control of established cardi-
ovascular risk factors such as diabetes, arterial hyperten-
sion, obesity and dyslipidemia [2]. Beside these traditional 
cardiovascular risk factors, there is growing interest in 
new potential cardiovascular risk factors, which may help 
improving patients’ treatment and/or prognosis. One of 
these potential new risk factors is cardiac adipose tissue, 
since recent studies reported that increased cardiac adi-
pose tissue in the setting of metabolic syndrome [3] (and 
in particular accumulation of epicardial adipose tissue) is 
associated with the presence of coronary artery disease 
[4–6], as well as with cardiovascular adverse events [7, 8].
Steroid medication is known to imitate many effects 
of the metabolic syndrome [9]. However, the impact of a 
long-term steroid therapy on myocardial adipose tissue 
deposition in a clinical setting has not been investigated 
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so far. This is of special interest in the large group of 
patients with different rheumatic disorders, since these 
patients are often dependent on the long-term use of 
steroids.
Thus, our primary aim was to evaluate the impact 
of long-term steroid therapy on cardiac fat deposi-
tion in patients with rheumatic disorders. In addi-




Sixty-one consecutive patients presenting at our institu-
tion between October 2012 and November 2013 were 
prospectively enrolled if they fulfilled the following crite-
ria: (1) underlying rheumatic disorder; and (2) long-term 
steroid medication; and (3) successfully underwent cardi-
ovascular magnetic resonance (CMR) imaging. Patients´ 
medical history was reviewed in detail regarding dosage 
and duration of steroid therapy, and clustered in a high-
dose and a low-dose steroid group (definitions see below). 
Exclusion criteria were contraindications for CMR (e.g. 
pregnancy, pacemaker/implantable cardioverter defibril-
lator (ICD), glomerular filtration rate  <30  ml/min., pre-
vious adverse reactions to gadolinium, cochlea implant). 
Patients gave written informed consent according to the 
Declaration of Helsinki prior to inclusion in the study. 
The data collection and the study have been approved 
by the ethics committee of the University of Tübingen 
(527/2012B02).
Control group
Sixty-one age-, sex-, and body mass index (BMI) matched 
patients with no rheumatic disorder, and who never had 
been on steroids served as control group. Due to the 
paired matched character of the control group, these 
controls were further divided in two groups to match (1) 
the high-dose steroid group, and (2) the low-dose steroid 
group. Baseline characteristics of the patients with ster-
oid therapy and the paired matched control groups can 
be viewed in Table 1.
CMR protocol
Electrocardiogram (ECG) gated CMR imaging was per-
formed in breath-hold using a 1.5T Aera (Siemens-
Healthcare, Germany) in line with recommendations 
of the Society of Cardiac Magnetic Resonance (SCMR) 
and the European Society of Cardiology (ESC) Work-
ing Group EuroCMR, respectively [10]. Cine short axis 
CMR images were prescribed every 10 mm (slice thick-
ness 6  mm) from base to apex. In-plane resolution was 
typically 1.2 × 1.8 mm. Cine CMR was performed using a 
steady-state–free-precession-sequence.
CMR analysis
Scans were analyzed by consensus of two experienced 
observers, who were blinded to patient identity and clini-
cal information.
Cine images were evaluated as described previously 
[11]. In brief, endocardial and epicardial borders were 
outlined on the short axis cine images. Volumes and ejec-
tion fraction were derived by summation of epicardial 
and endocardial contours.
A single cine four-chamber view of each patient was 
used for quantification (in cm2) of epicardial and peri-
cardial fat layer (definitions see below), as described else-
where [3, 12]. In brief, after careful examination of all 
phases of the cine four-chamber view image, epicardial 
and pericardial fat layers were outlined in the end-dias-
tolic image with commercially available Siemens Argus 
software (Siemens-Healthcare, Germany), also see Fig. 1. 
Intra- and inter-observer variability was evaluated in 30 
patients (15 steroid-treated patients, 15 steroid-naïve 
controls) on separate occasions.
Definitions and variables
High-dose steroid group: Patients with an intake 
of  >7.5  mg prednisone equivalent per day (Cushing 
threshold) for at least 6 months before CMR exam [13].
Low-dose steroid group: Patients with an intake 
of  <7.5  mg prednisone equivalent per day for at least 
6 months before CMR exam [13].
Long-term steroid use: Use of prednisone (or equiva-
lent) daily, minimum during the past 6  months before 
CMR exam [13].
All glucocorticoid preparations were calculated to 
prednisone equivalent doses as described elsewhere [14].
Epicardial fat: Adipose tissue layer located between the 
myocardium and the visceral pericardium [3].
Pericardial fat: Intrathoracic adipose tissue located out-
side the parietal pericardium [12].
Body mass index (BMI): Weight (in kilograms) divided 
by the square of the height (in meters).
CAD: recognized or unrecognized myocardial infarc-
tion, or CAD with >20 % luminal diameter stenosis in at 
least one major coronary artery or its branches [15].
Arterial hypertension: Systolic blood pressure above 
140 mmHg, diastolic blood pressure above 90 mmHg, or 
antihypertensive treatment [8].
Diabetes: Fasting plasma glucose level of ≥126  mg/dl 
or treatment with either insulin or a hypoglycemic agent.
Hypercholesterolemia: Total cholesterol level >200 mg/
dl or use of cholesterol-lowering medication.
Smoker: Current or ever smokers.
Family history of CAD: Symptomatic CAD in a male 
first-degree relative before age 55, or a female first-degree 
relative before age 65 [16].
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Metabolic syndrome: Patients had to fulfill the crite-
ria of the International Diabetes Federation, which were 
described in detail previously [17].
Statistical analysis
All continuous variables were tested for normality using 
the Kolmogorov–Smirnov test. Normally distributed 
continuous variables were expressed as means (with 
standard deviation) and skewed variables were presented 
as medians (with quartiles). Comparisons between 
groups were made using the Mann–Whitney U test or 
the Fisher’s exact test, as appropriate. Comparisons 
between paired groups were made using the Wilcoxon 
test. Intra- and inter-observer variability was assessed 
via intra-class correlation coefficients (ICC). Absolute 
agreement ICCs were calculated by a two-way mixed 
model for single measures. P values (two-tailed) of <0.05 
were considered significant. All statistical analyses were 
performed using the GraphPad Prism statistical software 
package (GraphPad, San Diego, CA, USA) and SPSS Sta-
tistics version 23 (IBM Corporation, Armonk, NY, USA), 
respectively.
Table 1 Baseline patient characteristics
Values are mean ± SD, median [IQR], n (%)
BMI body mass index, LVEF left ventricular ejection fraction, LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic volume, CAD coronary 
artery disease, LDL low-density lipoprotein, HDL high-density lipoprotein, ANCA anti-neutrophil cytoplasmic antibody, RA rheumatoid arthritis
a ANCA pos. vasculitis: granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, microscopic polyangiitis
b Other vasculitis: IgA vasculitis, Kawasaki disease, Takayasu’s Arteritis, giant cell arteritis
c Collagenosis: systemic lupus erythematosus, overlap syndrome, systemic sclerosis, sjogrens syndrome
d Others: Behçet’s disease, sarcoidosis
Variable Steroid-treated patients Steroid-naïve controls p
n 61 61 –
Age (years) 54 ± 16 54 ± 16 –
Female 43 (70.5) 43 (70.5) –
BMI, kg/m2 27 ± 6 27 ± 6 –
LVEF, % 62 [60–67] 66 [59–69] 0.16
LVEDV, ml 121 [108–136] 117 [102–140] 0.99
LVESV, ml 44 [35–56] 42 [33–5] 0.74
Epicardial fat, cm2 5.7 [3.5–9.1] 4.2 [1.3–5.8] <0.001
Pericardial fat, cm2 13.0 [6.1–26.8] 6.4 [1.6–15.4] <0.01
CAD 9 (14.8) 0 <0.01
Arterial hypertension 33 (54.1) 23 (37.7) 0.10
Systolic blood pressure, mmHg 127 ± 20 118 ± 16 <0.05
Diastolic blood pressure, mmHg 74 ± 10 71 ± 8 0.18
Diabetes 10 (16.4) 1 (0.2) <0.01
Hypercholesterolemia 10 (16.4) 13 (21.3) 0.44
Total cholesterol, mmol/l 5.34 ± 1.24 5.18 ± 0.95 0.32
LDL cholesterol, mmol/l 3.26 ± 1.02 3.07 ± 0.95 0.41
HDL cholesterol, mmol/l 1.51 ± 0.49 1.43 ± 0.52 0.51
Triglycerides, mmol/l 4.56 ± 3.38 3.56 ± 1.77 0.05
Smoker 12 (19.7) 14 (23.0) 0.83
Family history of CAD 27 (44.3) 13 (21.3) <0.05
Duration steroid therapy, months 30 [8–93] – –
Daily steroid dose at inclusion, mg 10 [5–30] – –
Metabolic syndrome 2 (3.2) 0 0.50
ANCA pos. vasculitisa 21 (34.4) – –
Other vasculitisb 6 (9.8) – –
Collagenosisc 20 (32.8) – –
RA 10 (16.4) – –
Sarcoidosis 2 (3.3) – –
Othersd 2 (3.3) – –
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Results
Patient population
In total 122 patients were included in the final analy-
sis: n = 61 patients received long-term steroid therapy 
due to underlying rheumatic disorder, n =  61 patients 
served as an age, gender and BMI-matched ster-
oid-naïve control group. At inclusion, patients were 
54 ± 16 years of age, predominantly female (71 %), with 
a mean BMI of 27 ± 6 kg/m2. Median disease duration 
was 4.7 [0.8–8.2] years. Functional CMR parameters did 
not differ significantly between both groups. However, 
patients on steroid therapy showed larger epicardial 
5.7 [3.5–9.1] cm2, as well as pericardial 13.0 [6.1–26.8] 
cm2 fat areas compared to paired matched controls (4.2 
[1.3–5.8] cm2/6.4 [1.6–15.4] cm2, p  <  0.001, p  <  0.01, 
respectively). Additional clinical characteristics can be 
viewed in Table 1.
In the steroid group, duration of steroid therapy 
was 30 [8–93] months with a median daily prednisone 
dose at inclusion of 10 [5–30] mg. Of note, the preva-
lence of metabolic syndrome did not differ signifi-
cantly between the steroid group and controls; two out 
of 61 patients in the steroid group fulfilled criteria of 
metabolic syndrome, no patient in the control group, 
p = 0.5.
The majority of steroid-treated patients presented with 
ANCA positive vasculitis (34  %), followed by patients 
with collagenosis (33  %), and patients with rheumatoid 
arthritis (16 %).
Low-dose steroid group vs. high-dose steroid group
Clinical data of the steroid population divided in low-
dose and high-dose steroid groups are displayed in 
Table 2. Twenty-five (out of 61) patients were in the low-
dose steroid group, 36 (out of 61) patients were in the 
high-dose steroid group. BMI was higher in the high-dose 
steroid (28 ± 6 kg/m2) compared to the low-dose steroid 
group (25 ± 5 kg/m2, p < 0.05). Functional CMR param-
eters were similar between both groups. More patients in 
the high-dose steroid group (n = 7) had prevalent CAD 
than in the low-dose steroid group (n  =  2; p  =  0.29). 
Traditional cardiovascular risk factors did not differ sig-
nificantly between both groups. Metabolic syndrome was 
present in two patients of the high-dose steroid group, no 
patient in the low-dose steroid group fulfilled criteria of 
metabolic syndrome, p = 0.51.
Epicardial and pericardial fat
Focusing on patients with high-dose steroid therapy 
(>7.5  mg prednisone equivalent daily during the past 
6  months) revealed, that those patients had signifi-
cantly more epicardial fat compared to matched steroid-
naïve controls: 7.2 [4.2-11.1] cm2 vs. 4.4 [1.0–6.0] cm2, 
p  <  0.001. Furthermore, patients on high-dose steroid 
therapy also had significantly more epicardial fat com-
pared to patients on low-dose steroid therapy (<7.5  mg 
prednisone equivalent daily during the past 6  months): 
7.2 [4.3–11] cm2 vs. 4.7 [2.1–7.5] cm2, p < 0.01, see Fig. 2.
Among patients on high-dose steroid therapy, CMR 
revealed significantly more pericardial fat compared 
to steroid-naïve controls: 18.6 [8.9–38.2] cm2 vs. 10.7 
[4.7–26.8] cm2, p < 0.05. Additionally, patients on high-
dose steroid therapy had significantly more pericardial fat 
compared to patients on low-dose steroid therapy: 18.6 
[8.9–38.2] cm2 vs. 8.3 [2.3–18.7] cm2, p < 0.001.
No significant differences in epicardial and pericardial 
fat deposition could be detected between patients on 
low-dose steroid therapy and paired matched controls, 
see also Fig. 2.
Intra-observer reproducibility was high with an ICC of 
0.97 for epicardial fat and 0.98 for pericardial fat assess-
ment, respectively. Inter-observer reproducibility showed 
an ICC of 0.95 for epicardial and 0.96 for pericardial fat, 
respectively.
Cardiac fat and BMI
We found a correlation between epicardial and pericar-
dial fat and the BMI of patients in the steroid group, see 
Fig. 3. This holds also true for epicardial fat and BMI in 
the high-dose steroid group (p  <  0.001), as well as for 
pericardial fat in the low-dose steroid group, p  <  0.05. 
Furthermore, statistical analysis revealed a trend for peri-
cardial fat in the high-dose steroid group to be related to 
Fig. 1 Determination of epicardial and pericardial adipose tissue: Epi-
cardial (shown in red) and pericardial (shown in blue) contours were 
drawn in the end-diastolic image in a CMR 4-chamber view
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Table 2 Clinical data of steroid population
Values are mean ± SD, median [IQR], n (%); abbreviations see Table 1
Variable Low-dose steroid group High-dose steroid group p
n 25 36 –
Age (years ± SD) 52 ± 19 55 ± 14 0.60
Female 18 (72.0) 25 (69.4) –
BMI, kg/m2 25 ± 5 28 ± 6 <0.05
LVEF,  % 62 [61–71] 62 [56–65] 0.19
LVEDV, ml 120 [100–136] 121 [108–137] 0.64
LVESV, ml 42 [30–56] 45 [37–57] 0.22
Epicardial fat, cm2 4.7 [2.1–7.5] 7.2 [4.2–11.1] <0.01
Pericardial fat, cm2 8.3 [2.3–18.7] 18.6 [8.9–38.2] <0.001
CAD 2/25 (8.0) 7/36 (19.4) 0.29
Arterial hypertension 11 (44.0) 22 (61.1) 0.09
Systolic blood pressure, mmHg 123 ± 16 128 ± 21 0.23
Diastolic blood pressure, mmHg 74 ± 9 73 ± 10 0.81
Diabetes 3 (12.0) 7 (19.4) 0.51
Hypercholesterolemia 2 (8.0) 8 (22.2) 0.18
Total cholesterol, mmol/l 5.2 ± 3.12 5.37 ± 1.19 0.64
LDL cholesterol, mmol/l 3.2 ± 1.11 3.25 ± 0.98 0.88
HDL cholesterol, mmol/l 1.48 ± 0.52 1.52 ± 0.48 0.77
Triglycerides, mmol/l 4.46 ± 3.28 4.53 ± 3.57 0.95
Smoker 5 (20.0) 7 (19.4) 1.00
Positive family history of CAD 12 (48.0) 15 (41.7) 0.79
Daily steroid dose at inclusion, mg 5.0 [3.8–7.5] 15 [10–28] 0.46
Metabolic syndrome 0 2 (5.5) 0.51
Fig. 2 Values of epicardial and pericardial fat deposition in steroid-treated patients and matched steroid-naïve controls. a The high-dose ster-
oid group (>7.5 mg prednisone equivalent daily) showed significant higher amounts of epicardial fat than the low-dose steroid group (<7.5 mg 
prednisone equivalent daily) and the age, sex and BMI matched steroid-naïve controls. In addition, the amount of epicardial fat was not significant 
different between low-dose steroid patients and the control group. b Likewise, these results could be confirmed for pericardial fat
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BMI (p = 0.06), and also for epicardial fat in the low-dose 
steroid group (p =  0.1). No correlation of epicardial or 
pericardial fat deposition with BMI could be detected in 
the control group, see Fig. 3.
Dividing patients on steroids and matched controls 
in an obese (BMI  >  25  kg/m2) and a non-obese group 
(BMI  <  25  kg/m2) revealed, that steroid patients with a 
BMI > 25 kg/m2 showed significantly more epicardial fat 
than steroid patients with a BMI < 25 kg/m2 (p < 0.0001). 
Similar results could be found for pericardial fat in the 
steroid-treated group (p = 0.001), see Fig. 4. However, no 
statistical significant difference in cardiac fat distribution 
between obese and non-obese control patients could be 
reported. Typical CMR results are displayed in Fig. 5.
Discussion
To the best of our knowledge, this is the first study sys-
tematically evaluating the impact of long-term steroid 
use on cardiac fat deposition in patients with different 
rheumatic disorders.
The main findings of the study are as follows: (1) Long-
term steroid use is associated with increased epicardial 
and pericardial fat deposition compared to steroid-naïve 
controls. (2) High-dose steroid therapy (>7.5  mg pred-
nisone equivalent daily) leads to higher amounts of 
epicardial and pericardial adipose tissue compared to 
low-dose steroid therapy. (3) Cardiac fat distribution cor-
relates with BMI in steroid treated patients, but not in 
steroid-naïve controls.
Thus, in awareness that cardiac fat may represent a new 
risk factor for CAD, patients with rheumatic disorders 
and long-term steroid therapy should be closely moni-
tored for early prevention of cardiovascular diseases.
Patient population
The mean patient age (54  years) and gender distribu-
tion (71 % female) are in line with previously published 
studies dealing with patients on long-term steroid treat-
ment [18]. As to expect, the steroid group demonstrated 
more epicardial and pericardial fat than the steroid-naïve 
control group. Diabetes was present in 10 patients of the 
steroid group, compared to only one patient in the con-
trol (p = 0.01), underscoring the need for glucose-lower-
ing medication in a cumulative dose-dependent manner 
in those patients [19, 20]. Moreover, the prevalence of 
arterial hypertension was increased in patients on steroid 
therapy vs. steroid-naïve controls (33 patients on steroids 
vs. 23 steroid-naïve controls, p  =  0.10). These findings 
are in line with results from other groups, demonstrat-
ing that steroid treatment contributes to development of 
arterial hypertension [21, 22].
In total 9 patients, all treated with steroids, showed evi-
dence of CAD, which might have several reasons: First, it 
is known that a high level of cortisol can lead to adverse 
events including cardiovascular disease mediated by 
effects which favors arterial hypertension, obesity, dia-
betes, hypercholesterolemia [23]. Second, it is known 
that some rheumatic disorders (e.g. rheumatoid arthritis, 
systemic lupus erythematosus (SLE), ANCA-associated 
vasculitis) [9], implicate an increased cardiovascular risk 
profile.
Low-dose steroid group vs. high-dose steroid group
Several studies suggested a dose-dependent interaction 
between steroids and the prevalence of adverse effects 
[13, 24]. Our steroid population was divided in a low-
dose (<7.5  mg prednisone equivalent daily) and high-
dose steroid group (>7.5 mg prednisone equivalent daily), 
taking steroids for at least 6 months, which is in line with 
other reports [13, 24]. Consequently, BMI was higher in 
the high-dose steroid group (28 ±  6 kg/m2) than in the 
low-dose steroid group (25 ± 5 kg/m2, p = 0.05). Inter-
estingly, patients in the high-dose steroid group showed 
increased prevalence of arterial hypertension and diabe-
tes compared to the steroid-naïve control group. How-
ever, this difference was not statistically significant.
Previous studies demonstrated that cardiac fat vol-
umes gradually increased with the number of metabolic 
syndrome components [25]. Of note, in our population 
CAD was more prevalent in the high-dose steroid group 
(n = 7) compared to the low-dose steroid group (n = 2; 
p =  0.29). This trend supports the hypothesis that high 
levels of steroids lead to cardiovascular disease mediated 
by steroid side effects such as arterial hypertension, obe-
sity, diabetes, or hypercholesterolemia [23, 26–28].
Epicardial and pericardial fat
Steroids are known to cause obesity [23], which is an 
important component of the metabolic syndrome. More-
over, previous studies could demonstrate that high-dose 
steroids yield an increase of visceral adipose tissues 
[29–31].
Epicardial fat surrounds the coronary arteries, and 
shares embryological origin with abdominal visceral fat, 
which is known to be an independent cardiovascular risk 
factor [32]. A frequent discussed mechanism for coro-
nary atherosclerosis are paracrine effects by the close 
proximity to the coronary arteries and the high content 
of secreted inflammatory factors in epicardial adipose 
tissue [33–35].
Patients with high-dose steroid therapy showed sig-
nificantly more epicardial fat compared to matched ster-
oid-naïve controls. Furthermore, patients on high-dose 
steroid therapy had significantly increased amounts of 
epicardial fat compared to patients on low-dose steroid 
therapy, pointing towards a cumulative dose-dependent 
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Fig. 3 Correlation of multiple parameters in steroid-treated patients and matched steroid-naïve controls. a, b Epicardial and pericardial fat with BMI 
in patients with steroid therapy. c, d Epicardial and pericardial fat in age, sex and BMI matched steroid-naïve controls. e, f Epicardial and pericardial 
fat with BMI in the low-dose steroid group (<7.5 mg prednisone equivalent daily). g, h Epicardial and pericardial fat with BMI in the high-dose ster-
oid group (>7.5 mg prednisone equivalent daily)
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effect of steroids on cardiac adipose tissue accumula-
tion. As described above, use of steroids might result in 
adverse effects, which are similar to the components of 
the metabolic syndrome. A recent study could show that 
patients with metabolic syndrome had significantly larger 
areas of epicardial and pericardial fat in comparison to 
subjects without metabolic syndrome [3]. In line with 
these results, our study revealed significantly elevated 
amounts of epicardial and pericardial adipose tissue in 
the steroid-treated group compared to steroid-naïve con-
trols. Of note, the results for epicardial fat in our high-
dose steroid group 7.2 [4.2–11.1] cm2 are in line with 
the amounts of epicardial fat in this latter study [3]: 8.4 
[3.9–17.5] cm2. Moreover, the amounts of pericardial fat 
in our high-dose steroid group 18.6 [8.9–38.2] cm2 nicely 
matches the results of pericardial fat in patients with 
metabolic syndrome 19.1 [6.2–61.3] cm2, strongly sug-
gesting similar effects of a (high-dose) long-term steroid 
therapy and the metabolic syndrome on cardiac adipose 
tissue deposition [3, 12].
Cardiac fat and BMI
In the steroid treated group epicardial and pericardial 
fat correlated with patients BMI, also see Fig.  3. Look-
ing at patients with high-dose steroid therapy, this holds 
also true for the correlation of epicardial fat with BMI 
(p < 0.0001). Moreover, there was a trend for correlation 
of pericardial fat with BMI in the high-dose steroid group 
(p = 0.06). In the low-dose steroid group there was also a 
trend for correlation of epicardial fat and BMI (p = 0.1), 
whereas pericardial fat correlated with BMI (p  <  0.05), 
suggesting that even in low-dose steroid treated patients 
weight gain is yielding increased cardiac adipose tissue 
accumulation.
Dividing steroid treated patients and matched controls 
in an obese (BMI  >  25  kg/m2) and a non-obese group 
(BMI < 25 kg/m2) [36] revealed, that patients within the 
steroid group and a BMI > 25 kg/m2 showed significantly 
more epicardial fat than patients in the steroid group with 
BMI  <  25  kg/m2 (p  <  0.0001). Similar results could be 
found for pericardial fat in the steroid group (p = 0.001). 
However, no correlation of epicardial or pericardial fat 
deposition with BMI could be detected in the steroid-
naïve control group. These findings confirm another large 
study measuring epicardial fat thickness by computed 
tomography in 970 patients. In this study epicardial fat 
was associated with presence of CAD, as well as CAD 
severity, but not with BMI, supporting our results [37].
Clinical implications
On the basis of the data presented, it may be safe to 
assume that patients with rheumatic disorders on long-
term steroid therapy suffer from increased cardiac fat 
deposition compared to steroid-naïve controls. Further-
more, this effect seems to be dose-dependent, resulting 
in higher amounts of cardiac fat in patients with long-
term use of >7.5 mg prednisone equivalent/day. Adding 
this new additional cardiovascular risk factor to our per 
se high-risk population for CAD, careful cardiovascular 
monitoring is mandatory.
Fig. 4 Comparison of epicardial and pericardial fat deposition in steroid-treated patients vs. controls with BMI >25 and BMI <25. a Amounts of 
epicardial fat in steroid-treated patients with BMI >25 (obese) and <25 (non-obese) compared to steroid-naïve controls. b Amounts of pericardial fat 
in steroid-treated patients with BMI >25 and <25 compared to steroid-naïve controls
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Moreover, as stated by the European League Against 
Rheumatism (EULAR) recommendations on systemic 
steroid use [38], there should be effort to achieve a maxi-
mum of effectiveness with a minimum of toxicity.
Further large, randomized, multi-center studies are 
needed to clarify if quantification of cardiac fat distribu-
tion in long-term steroid treated patients with rheumatic 
disorders has the potential to serve as a powerful diag-
nostic tool in detecting patients of additional cardiovas-
cular risk in this per se high-risk population for CAD.
Limitations
The quantification of epicardial and pericardial vol-
umes in a single CMR four-chamber view instead of 
covering the whole ventricle by volume quantifica-
tion in every short-axis slice might be susceptible to 
bias. However, recent reports demonstrated that this 
approach shows good correlation to the time-consuming 
Simpson method. This holds true for CMR imaging as 
well as for CT imaging [3, 12, 16, 39]. Another limita-
tion might be the lack of standardized reference values 
for epicardial and pericardial fat volumes, which pres-
ently restrict a more widespread use in clinical routine. 
However, our results in the high-dose steroid group are 
similar to the results reported in patients with metabolic 
syndrome [3], suggesting a common pathway between 
high-dose steroid effects (steroid induced fat distribu-
tion) and effects in patients with metabolic syndrome. 
Moreover, there are different confounders, which must 
be addressed. First, we cannot exclude confounding by 
indication, since higher doses of steroids might be pre-
scribed to those patients with more severe course of the 
disease. Second, patients were not paired-matched for 
arterial hypertension and CAD. Third, it is ambiguous, 
whether rheumatic disorders themselves might have 
impact on the distribution of cardiac adipose tissue. 
Fourth, our control group was not matched for rheu-
matic disorders, since a potential deprivation of steroids 
would have been largely unethical. Thus, in some of the 
results, it might be difficult to differentiate if they are 
attributable to steroid use only, to disease severity, or a 
combination of both.
Conclusions
The present data suggest that the use of steroids in 
patients with different rheumatic disorders is associated 
with increased cardiac adipose tissue accumulation. This 
effect seems to be stronger in patients with high-dose 
prednisone equivalent doses (>7.5  mg daily for at least 
6  months) than in patients with low-dose prednisone 
equivalent doses, suggesting a cumulative dose-depend-
ent effect.
Fig. 5 Patient examples of 4-chamber oriented end-diastolic images 
for determination of epicardial and pericardial fat. a, b 55-year old 
male with high-dose steroid treated rheumatoid arthritis for more 
than 8 years. Patients BMI was 27.8 kg/m2, beside arterial hypertension 
he suffered from diabetes. CMR 4-chamber view revealed extensive 
epicardial fat deposition (shown in red) and pericardial fat deposition 
(shown in blue). c, d Age, sex and BMI matched steroid-naïve control 
to the high-dose steroid-treated patient in panels A/B with less 
amounts of epicardial and pericardial fat. e, f 49-year old steroid-naïve 
female (control group) with moderate epi- and pericardial fat deposi-
tion despite a high elevated BMI of 41.2 kg/m2 (obese class III). g, h 
69-year old steroid-naïve female (control group) with a BMI of 26.8 kg/
m2. Despite only moderate elevated BMI and no history of steroid 
intake, this patient showed considerable amounts of epi- and pericar-
dial fat, underlining the lack of association between BMI and amounts 
of epi- and pericardial fat in the steroid-naïve control group
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